Smith & Nephew Plc ECC endorsed by Royal College of Surgeons
April 18 2018 - 2:00AM
RNS Non-Regulatory
TIDMSN.
Smith & Nephew Plc
18 April 2018
Smith & Nephew's Expert Connect Centre endorsed by Royal
College of Surgeons
18 April 2018
Smith & Nephew (LSE:SN, NYSE:SNN), the global medical
technology business, is pleased to announce its state-of-the-art
Expert Connect Centre ('ECC') in Watford, UK has become the first
commercial surgical training facility in Europe to be accredited by
the Royal College of Surgeons.
Widely regarded as the gold standard for accreditation, the
Royal College of Surgeons endorsement follows an in-depth
assessment of the facilities, resources and portfolio offered at
the ECC. The recognition enables delegates to receive Continuing
Professional Development (CPD) points when attending Smith &
Nephew sessions, demonstrating their commitment to developing their
surgical skills.
"Smith & Nephew's Expert Connect Centre offers facilities of
the highest quality; its education portfolio is extensive and there
was a clear demonstration and a broad confidence in each of the
components assessed" said Professor Paul O'Flynn, Quality Assurance
and Accreditation, Royal College of Surgeons.
"We're pleased to offer the ECC this accreditation and look
forward to continue seeing the centre enable surgeons to achieve
the highest standards of care."
"This endorsement from the Royal College of Surgeons is a huge
honour and recognition of the quality of our medical training and
education. We're very proud to be regarded as a benchmark
professional development facility and look forward to welcoming
more healthcare professionals to the Expert Connect Centre as we
continue to support them in their vital work improving patients'
lives," said Massimiliano Colella, President Europe and Canada,
Smith & Nephew.
Since its opening in February 2017, almost 2000 healthcare
professionals from the UK and across the globe, including Canada,
Japan and China have received training at the ECC. Designed to
encourage interaction, the centre offers the same set-up as 14
hospital operating rooms, providing an environment where surgeons
and nurses can learn new techniques and refine skills first hand,
to ensure the safe and effective use of Smith & Nephew
products. It boasts a large auditorium, seating over 80, for
plenary sessions and uses the latest broadcasting and recording
technology to capture and share the learning experience.
- ends -
Enquiries
Media
Charles Reynolds
Smith & Nephew +44(0)1923 477314
Matt Copeman
Smith & Nephew +44 (0)1923 477385
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2017 were
almost $4.8 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEASLXFSPPEFF
(END) Dow Jones Newswires
April 18, 2018 03:00 ET (07:00 GMT)
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From Apr 2024 to May 2024
Smith & Nephew (LSE:SN.)
Historical Stock Chart
From May 2023 to May 2024